Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients

N/AApproved For MarketingNCT05463939

Janssen Research & Development, LLC

Overview

The purpose of this expanded access treatment protocol is to provide patients access to teclistamab prior to market authorization. The program is limited to patients with relapsed or refractory multiple myeloma who have exhausted all treatment options available as local standard of care and who are not eligible for a teclistamab clinical trial.

Study Type

EXPANDED_ACCESS

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

TeclistamabDRUG

Teclistamab will be administered subcutaneously (SC).

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient diagnosed with Relapsed or Refractory Multiple Myeloma * Patient exhausted all commercially approved and clinically appropriate (not patient or physician preference) treatment options, and is ineligible for a clinical trial

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.